GCS Ramsay Santé pour l'Enseignement et la Recherche
Quick facts
Marketed products
- C1 Inhibitor Human · Immunology / Rare Genetic Disorders
C1 Inhibitor Human is a plasma-derived protein replacement therapy that restores deficient or dysfunctional C1 esterase inhibitor to prevent excessive bradykinin generation and control hereditary angioedema attacks. - Rachianesthesia · Other
- standard pain relievers · Pain Management
Standard pain relievers work by inhibiting cyclooxygenase (COX) enzymes or blocking pain signal transmission to reduce pain perception.
Phase 1 pipeline
- anaesthesia with morphine
- anaesthesia without opiates
- Intravenous lidocaine administration
- Neuroleptanalgesia · Neuroscience
- Neuroleptanalgesic treatment
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- GCS Ramsay Santé pour l'Enseignement et la Recherche portfolio CI brief
- GCS Ramsay Santé pour l'Enseignement et la Recherche pipeline updates RSS
Frequently asked questions about GCS Ramsay Santé pour l'Enseignement et la Recherche
What are GCS Ramsay Santé pour l'Enseignement et la Recherche's marketed drugs?
Top marketed products include C1 Inhibitor Human, Rachianesthesia, standard pain relievers.
Related
- C1 Inhibitor Human · Immunology / Rare Genetic Disorders
- Rachianesthesia · Other
- standard pain relievers · Pain Management
- Sector hub: All tracked pharma companies